

B¹ 13. (Once Amended) A method for the prophylactic treatment of a subject at risk of developing a cardiovascular disorder which comprises treating the subject with a therapeutically effective amount of a cyclooxygenase-2 inhibitor, or a pharmaceutically-acceptable salt thereof in combination with a lipid lowering drug.

B² 15. (Once Amended) The prophylactic treatment method of claim 13 wherein said lipid lowering drug is selected from the group consisting of (1) an IBAT inhibitor, (2) a fibrate, (3) niacin, (4) a statin, (5) a CETP inhibitor and (6) a bile acid sequestrant.

B³ 24. (Once Amended) A method for preventing atherosclerosis in a subject at risk of developing atherosclerosis which comprises treating the subject with a therapeutically effective amount of a cyclooxygenase-2 inhibitor, or a pharmaceutically-acceptable salt thereof in combination with a lipid lowering drug.

B⁴ 26. (Once Amended) The method of claim 24 wherein said lipid lowering drug is selected from the group consisting of (1) an IBAT inhibitor, (2) a fibrate, (3) niacin, (4) a statin, (5) a CETP inhibitor and (6) a bile acid sequestrant.

B⁵ 32. (Once Amended) A pharmaceutical composition comprising, in a single formulation, a combination of a therapeutically effective amount of a cyclooxygenase-2 inhibitor, or a pharmaceutically-acceptable salt thereof and a therapeutically effective amount of a lipid lowering drug.

B⁶ 34. (Once Amended) The composition of claim 32 wherein said lipid lowering drug is selected from the group consisting of (1) an IBAT inhibitor, (2) a fibrate, (3) niacin, (4) a statin, (5) a CETP inhibitor and (6) a bile acid sequestrant.

REMARKS

Applicants have amended the application by incorporating the dependent claims 14, 25 and 33 into the related independent claims 13, 24 and 32 respectively and